United Therapeutics Says FDA Accepts Supplemental Filing for Nebulized Tyvaso in IPF
MT newswire2026/09/02 11:25Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japan's 20-year government bond auction sees weak demand as bid-to-cover ratio drops sharply to 3.64, marking the lowest demand of the year
Japan's 20-year government bond auction saw weak demand, with the bid-to-cover ratio falling to 3.64 and the tail widening to its largest in a year. The market is concerned about fiscal budget issues and rising yields.

Google-backed AI pharmaceutical company raises $5 billion in funding, doubling the previous round
The current funding round for Isomorphic Labs is co-led by top VCs including Sequoia Capital and Andreessen Horowitz. This round comes only six months after the previous $2.1 billion Series B, with the scale more than doubling. By 2026, total financing in the AI pharmaceutical sector has reached a record high of $23.2 billion, with Anthropic and OpenAI also entering the field.
Japanese stocks closed up by 0.28%

Report: Apple Plans to Establish Multi-Year DRAM Agreement with Samsung, Deliveries to Begin in First Half of 2027
Apple and Samsung are in negotiations for a long-term DRAM chip supply agreement lasting four to five years, with deliveries expected to start in the first half of 2027. The agreement is expected to include a minimum supply commitment and set pricing linked to the market. Currently, Apple is one of the few major tech companies that have yet to sign a long-term DRAM supply deal with Samsung.
